PGS Sample Set (PSS): PSS001045

Phenotype Cases are individuals with type 2 diabetes (T2D). T2D cases were defined as individuals with (1) a T2D diagnosis by a physician/medical professional and use of medication for treatment of diabetes,and/or (2)a fasting(R8h)blood glucose measurement R126 mg/dL indicated in examination records. For the BMBB cohort T2D diabetes status was defined from algorithms extracted from electronic medical record (EMR) and includes family history of T2D as an exclusion criteria. For T2D cases, BMBB defined medications using unique RxNorm codes at an ingredient level and defined laboratory tests using the logical observations identifiers names and codes (LOINC) standard (https://www.phekb.org/phenotype/type-2-diabetes-mellitus). BioMe included all patients with ICD-9-CM codes of 250.x0 or 250.x2, except for codes 250.10 and 250.12 (indicative of T2D with ketoacidosis, a condition also closely associated with T1D), patients on T2D medications and/or insulin at any time, and all patients with abnormal glucose (>200 mg/dl) or hemoglobin A1c (HbA1c; ≥6.5%) laboratory test results. For the MEC cohort, T2D cases were defined using the following criteria: (a) a self-report of diabetes on the baseline questionnaire, 2nd questionnaire or 3rd questionnaire; and (b) self-report of taking medication for T2D at the time of blood draw; and (c) no diagnosis of T1D in the absence of a T2D diagnosis from the California Office of Statewide Health Planning and Development (OSHPD) for California Residents. In addition, cases included individuals who were linked to the diabetes registries of Hawaii Medical Service Association (HMSA) or Kaiser Permanente Hawaii (KPH) health plans, or who were designated as diabetic in the Chronic Conditions Data Warehouse (CCW) of Medicare. For the WHI cohort, T2D was documented at baseline by self-report in which each woman was asked whether she had ever been told that she had “sugar diabetes” by her physician. Incident diabetes during follow-up was documented by self-report at each semi-annual contact, when participants were asked, “Since the date given on the front of this form, has a doctor prescribed any of the following pills or treatments?” Choices included “pills for diabetes” and “insulin shots for diabetes.”.
Sample Ancestry Asian unspecified

Sample Numbers

Total number
4,576 individuals
Detailed numbers
2,004 cases (43.79%)
2,572 controls
Number of Cohort(s) 3
Sample distribution

Cohort(s)

Cohort Short Name Cohort Full Name Previous/other/additional names (e.g. sub-cohorts)
BioMe BioMe® BioBank Program (Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai) BioMe Biobank (BMBB), MT. SINAI BioMe Biobank Platform (IMP), Charles R Bronfman Institute for Personalized Medicine - IPM / BioBank Genome Wide Association Study of Cardiovascular, Renal and Metabolic Phenotypes (IPM), Charles R Bronfman Institute for Personalized Medicine - IPM / BioBank Genome Wide Association Study of Cardiovascular, Renal and Metabolic Phenotypes I (IPM I), Charles R Bronfman Institute for Personalized Medicine - IPM / BioBank Genome Wide Association Study of Cardiovascular, Renal and Metabolic Phenotypes II (IPM II), IPM_EA_Affy, IPM_EA_Illu, Mount Sinai BioMe BioBank (Mount Sinai)
MEC Multiethnic Cohort Study of Diet and Health
WHI Womens Health Initiative

Additional information

Possible sample overlap with this dataset and the datasets used to source/develop GRS582_T2Dmulti and GRS582_T2Dasn.